Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHINE1: Pharmacokinetics of IV Sildenafil in Neonates With Hypoxic-ischemic Encephalopathy
NCT06810284Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sildenafil in hypoxic-ischemic encephalopathy (HIE), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Plasma concentrations of Sildenafil up to 5 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sildenafil
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT06810284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810284.